Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2010
11/25/2010US20100297187 Peptide sequences and compositions
11/25/2010US20100297186 Multicomponent or monocomponent vaccine to be used against chagas disease, pharmaceutical compositions containing them, procedure for the obtention of immunogen of said vaccines, and nucleic acid used in said procedure
11/25/2010US20100297185 Mycobacterial mutants affecting host apoptosis
11/25/2010US20100297184 Vaccines
11/25/2010US20100297183 Immunogenic streptococcus proteins
11/25/2010US20100297182 Injectable Amino-acid Composition
11/25/2010US20100297181 AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
11/25/2010US20100297180 Botulinum neurotoxin vaccine
11/25/2010US20100297179 Immunology Treatment for Biofilms
11/25/2010US20100297178 Novel genes and proteins of brachyspira hyodysenteriae and use of same for diagnosis and therapy
11/25/2010US20100297177 Mutated parvovirus structural proteins as vaccines
11/25/2010US20100297176 Polyinosinic Acid - Polycytidylic Acid - Based Adjuvant
11/25/2010US20100297175 Mutations in a toll-like receptor motif in the NS4B of classical swine fever virus strain brescia influences virulence in swine
11/25/2010US20100297174 Influenza virus vaccines and uses thereof
11/25/2010US20100297173 Prophylactic and therapeutic immunization against protozoan infection and disease
11/25/2010US20100297172 Replication-defective arenavirus vectors
11/25/2010US20100297171 Development of a preventive vaccine for filovirus infection in primates
11/25/2010US20100297170 Vaccines
11/25/2010US20100297169 Novel Neutralizing Immunogen (NIMIV) of Rhinovirus and its Use for Vaccine Applications
11/25/2010US20100297168 Lentiviral gene transfer vectors and their medicinal applications
11/25/2010US20100297167 Method for the Production of Recombinant Virus, DNA Constructs, Recombinant Virus and Vaccine Compositions
11/25/2010US20100297166 Meningococcal Oligosaccharide Linked Polysaccharides and Diptheria Protein Conjucate Vaccine for All Ages
11/25/2010US20100297165 Immunostimulatory combinations of tlr ligands and methods of use
11/25/2010US20100297164 Chlamydial Antigens
11/25/2010US20100297163 Recombinant malaria vaccine
11/25/2010US20100297162 S. epidermidis antigens
11/25/2010US20100297161 Immunoprotective influenza antigen and its use in vaccination
11/25/2010US20100297160 High Molecular Weight Amyloid Beta As a Carrier for the Oral Delivery of Vaccine Antigens
11/25/2010US20100297159 Thomsen-friedenreich disaccharide modified immunogen (tfd), preparation procedure, compositions comprising it, uses, and treatment methods
11/25/2010US20100297158 Anticancer vaccine and diagnostic methods and reagents
11/25/2010US20100297157 Vaccine therapy for choroidal neovascularization
11/25/2010US20100297156 Analogues of phosphatidylinositol mannosides
11/25/2010US20100297155 Phosphazene hydrogels with chemical corss-link, preparation method thereof and use thereof
11/25/2010US20100297154 CD40 ligand-enhanced cells and methods of modulating an immune response to an antigen
11/25/2010US20100297153 Binding molecules for treatment and detection of cancer
11/25/2010US20100297152 Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
11/25/2010US20100297151 Antibodies against human il-21 receptor and uses therefor
11/25/2010US20100297150 Disease treatment via antimicrobial peptide inhibitors
11/25/2010US20100297149 Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
11/25/2010US20100297148 Cd38 modulated chemotaxis
11/25/2010US20100297147 Compositions and methods for modulating tlr14 activity
11/25/2010US20100297146 Immune system programming through b7-dc
11/25/2010US20100297145 Apoptosis promoter, cell proliferation inhibitor, prophylactic/therapeutic agent for cancer, screening method for the promoter, inhibitor or agent
11/25/2010US20100297144 Multitype hpv peptide compositions and methods for treatment or prevention of human papillomavirus infection
11/25/2010US20100297143 Methods for treating psoriasis
11/25/2010US20100297142 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
11/25/2010US20100297141 Anti-adhesin based passive immunoprophlactic
11/25/2010US20100297140 Uses of antibodies
11/25/2010US20100297139 Methods and compositions for the treatment of proteinuric diseases
11/25/2010US20100297138 Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
11/25/2010US20100297137 Hematopoietic Lineage Cell Specific Protein (HS1) as a Marker for Lymphoid Malignancy
11/25/2010US20100297136 Gastric and Prostate Cancer Associated Antigens
11/25/2010US20100297135 Epitope for neutralizing antibodies
11/25/2010US20100297134 Humanised antibodies with anti-tumour activity
11/25/2010US20100297133 Immunogenic Polypeptides and Monoclonal Antibodies
11/25/2010US20100297132 Monoclonal antibody
11/25/2010US20100297131 Binding domain of plasmodium reticulocyte binding proteins
11/25/2010US20100297130 Protective anti-glucan antibodies with preference for beta-1,3-glucans
11/25/2010US20100297129 Method for extending pregnancy in patients exhibiting at least one symptom of preeclampsia and eclampsia
11/25/2010US20100297128 Gamma secretase modulators
11/25/2010US20100297127 Use of il-27 antagonists to treat lupus
11/25/2010US20100297126 Monoclonal Antibodies Specific to Hemagglutinin from Influenza Virus H5-Subtype and Uses Thereof
11/25/2010US20100297125 Methods of treating pain using antagonists of il-31, il-31ra and/or osmrb
11/25/2010US20100297124 Induced internalization of surface receptors
11/25/2010US20100297123 Combination therapy to inhibit t cell effector function
11/25/2010US20100297122 Formulations for taci-immunoglobulin fusion proteins
11/25/2010US20100297121 Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists
11/25/2010US20100297120 Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
11/25/2010US20100297119 Bone targeted alkaline phosphatase, kits and methods of use thereof
11/25/2010US20100297118 Therapeutic Cancer Treatments
11/25/2010US20100297117 Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
11/25/2010US20100297116 Uses of a glycoprotein vi (gpvi) inhibitor
11/25/2010US20100297115 Use of trkb antibodies for the treatment of respiratory disorders
11/25/2010US20100297114 Antigen presenting cell targeted vaccines
11/25/2010US20100297113 Quinone derivatives, pharmaceutical compositions, and uses thereof
11/25/2010US20100297112 Combinations comprising dmxaa for the treatment of cancer
11/25/2010US20100297111 Nanobodies against tumor necrosis factor-alpha
11/25/2010US20100297110 Antibody specific for human il-4 for the treatment of cancer
11/25/2010US20100297109 Methods for inhibiting fascin
11/25/2010US20100297108 Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
11/25/2010US20100297107 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
11/25/2010US20100297106 Pharmaceutical Formulations
11/25/2010US20100297105 Administering antisense oligonucleotides complementary to human apolipoprotein b
11/25/2010US20100297104 Dendritic macromolecule and a process thereof
11/25/2010US20100297103 Antibody having enhanced adcc activity and method for production thereof
11/25/2010US20100297102 Serotonin 5-ht3a receptors in treatment of neurological and psychiatric disorders
11/25/2010US20100297101 Integrin alpha. II .B.beta.3 Specific Antibodies and Peptides
11/25/2010US20100297095 Porifera-Based Therapeutic Compositions for Treating and Preventing Skin Diseases
11/25/2010US20100297077 Novel aryl potassium channel blockers and uses thereof
11/25/2010US20100297075 Combinational compositions and methods for treatment of cancer
11/25/2010US20100297072 Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
11/25/2010US20100297071 Immune response inducer
11/25/2010US20100297070 COMPOSITIONS AND METHODS FOR AMELIORATING CNS INFLAMMATION, PSYCHOSIS, DELIRIUM, PTSD or PTSS
11/25/2010US20100297066 Biodegradable peptide releasing polymers
11/25/2010US20100297064 Cytokine zalpha11 ligand antibodies
11/25/2010US20100297063 Cytokine zalpha11 ligand antibodies
11/25/2010US20100297061 Stat3 antagonists and their uses as vaccines against cancer
11/25/2010US20100297060 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
11/25/2010US20100297013 Humanized antibody
11/25/2010US20100297012 Humanized antibody
1 ... 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 ... 1823